To begin to address this issue, we screened two clinically relevant IGF inhibitors, CP-751,871 (figitumumab), an IGF1R blocking antibody, and BMS-754807, a small molecule dual IGF1R/InsR tyrosine kinase inhibitor, against a broad panel of 27 human T-ALL cell lines and scored for effects on overall cell growth/survival. This evidence concerns the gene IGF1R and acute lymphoblastic leukemia.